Transgene’s Combined General Meeting of May 5, 2023
May 05 2023 - 11:45AM
Business Wire
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of
Transgene’s (Paris:TNG) shareholders was held today (May 5, 2023)
at 9:00 a.m. at the Company’s headquarters (400 boulevard Gonthier
d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden,
France).
The meeting was chaired by Alessandro Riva, Chairman, to approve
the Company’s financial statements for the year ended December 31,
2022, and to vote on the other resolutions submitted for
approval.
The replay of the Combined General Meeting is available via
Transgene’s website and here.
The Combined General Meeting adopted all resolutions recommended
by the Board of Directors, including the versions of resolutions 9,
10 and 11 amended in session. The Combined General Meeting notably
has:
- Appointed one new Director:
- Carol Stuckley, MBA, as independent Director;
- Renewed the following Board Members’ mandates:
- Philippe Archinard, as non-independent Director, and the
company TSGH represented by Sandrine Flory;
- Benoît Habert, Marie Landel and Maya Saïd as independent
Directors.
Transgene’s Board of Directors is now comprised of the following
members:
- Dr. Alessandro Riva, Chairman;
- Hedi Ben Brahim, CEO;
- Alain Mérieux, Honorary Chairman;
- Philippe Archinard, Director;
- Jean-Luc Bélingard, Director;
- Prof. Jean-Yves Blay, independent Director;
- Sandrine Flory, Director (TSGH representative);
- Benoît Habert, independent Director;
- Marie Landel, independent Director;
- Maya Saïd, independent Director;
- Carol Stuckley, independent Director.
Detailed voting results are available on Transgene’s website,
under the heading Investors > General Meeting.
Carol Stuckley, MBA, independent Director
Ms. Carol Stuckley brings more than 35 years of experience as a
strategic and international financial executive, with proven
success leading finance teams and creating shareholder value for
healthcare companies.
She currently serves as a Board Director and Chairperson of the
audit committee of Centessa Pharmaceuticals, plc and previously
served on the board of directors of Ipsen (where she chaired the
audit committee) and Epizyme, Inc.
Ms. Carol Stuckley was formerly Chief Financial Officer and
Senior Vice President at HPS, which was acquired by TransUnion,
Inc. Previously, Carol was Chief Financial Officer, Vice President,
Finance at Galderma North America (Nestlé Skin Health S.A.). Carol
started her 23-year career at Pfizer Inc., where she held multiple
financial roles of increasing responsibility, and was most recently
Assistant Treasurer, Vice President, Finance and Corporate Officer
of Pfizer Inc.
A US citizen, Carol holds a Master of Arts Degree in Economics
and an MBA in International Finance from Temple University’s Fox
Business School.
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on
designing and developing targeted immunotherapies for the treatment
of cancer. Transgene’s programs utilize viral vector technology
with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of
therapeutic vaccines and oncolytic viruses:
TG4050, the first individualized therapeutic vaccine based on
the myvac® platform, TG4001 for the treatment of HPV-positive
cancers, as well as TG6002, BT-001 and TG6050, three oncolytic
viruses based on the Invir.IO® viral backbone.
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on social media: Twitter: @TransgeneSA – LinkedIn:
@Transgene
Disclaimer
This press release contains forward-looking statements, which
are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. The
occurrence of any of these risks could have a significant negative
outcome for the Company’s activities, perspectives, financial
situation, results, regulatory authorities’ agreement with
development phases, and development. The Company’s ability to
commercialize its products depends on but is not limited to the
following factors: positive pre-clinical data may not be predictive
of human clinical results, the success of clinical studies, the
ability to obtain financing and/or partnerships for product
manufacturing, development and commercialization, and marketing
approval by government regulatory authorities. For a discussion of
risks and uncertainties which could cause the Company’s actual
results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please
refer to the Risk Factors (“Facteurs de Risque”) section of the
Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230505005310/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media Transgene: MEDiSTRAVA Consulting David
Dible/Sylvie Berrebi +44 (0)203 928 6900
transgene@medistrava.com
Transgene (EU:TNG)
Historical Stock Chart
From Apr 2024 to May 2024
Transgene (EU:TNG)
Historical Stock Chart
From May 2023 to May 2024